We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Enzyme Technology Sanitizes Surgical Surfaces

By HospiMedica staff writers
Posted on 05 May 2006
Proteases are now available that substantially eliminate prions, the causative agents of mad cow disease and Creutzfeldt-Jakob disease (vCJD), from surgical surfaces.

Prionzym, manufactured by Genencor International (Palo Alto, CA, USA), can be used to disinfect medical instruments utilized in invasive surgeries, such as procedures related to the central nervous system, eyes, and tonsils, where prions have been shown to accumulate in the body. More...
Genencor plans to further develop its Prionzyme line of products targeted for disinfecting general instruments and for sanitizing equipment for the meat-processing industry. Prionzym was developed jointly with the United Kingdom's Health Protection Agency (HPA). The product has received the CE mark.

Prionzyme use for medical instruments combines the proprietary enzyme with specific temperature and pH conditions. The product is added as the first step in a presoak process with stainless steel instruments. Benefits of using enzymes include minimizing worker safety issues by reducing exposure to harsh chemicals and lessening the environmental impact, since enzymes biodegrade in disinfectant solution.

"Using the tools of biotechnology to address important issues facing the world today, Genencor is very pleased to commercialize the first enzyme technology to target this unconventional, infectious agent,” said Thomas Pekich, president of Genencor. "Our partnership with the HPA combined with the protease technology expertise we've built over the past two decades has been key to addressing this difficult problem.”

Prions, the causative agents of bovine spongiform encephalopathy (BSE) and its human form, vCJD, have been a concern in countries like the United Kingdom in recent years due to a lack of technology to reduce the risk from the protein-based particles on medical instruments.



Related Links:
Genencor International

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.